News Detail

Addex GABAB PAM candidate cuts cough in bleomycin IPF-related chronic cough model

PUBT · 04/29 05:00

Listen to the news

Addex GABAB PAM candidate cuts cough in bleomycin IPF-related chronic cough model

Addex Therapeutics on April 29, 2026 reported new preclinical results for its GABAB positive allosteric modulator candidate in a bleomycin-induced idiopathic pulmonary fibrosis-related chronic cough model.
Data were presented as already generated, with no future presentation disclosed.
Study showed sustained cough suppression over chronic dosing, supporting potential use in chronic cough management.
Results also indicated improvements in disease-related lung outcomes versus untreated animals, suggesting possible added benefit beyond symptom control.
Safety observations remained favorable in the model, reinforcing the compound’s positioning for longer-term development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290100PRIMZONEFULLFEED1001178541) on April 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.